GlaxoSmithKline plc (LON:GSK) insider Emma Walmsley bought 7 shares of GlaxoSmithKline stock in a transaction that occurred on Friday, August 9th. The shares were acquired at an average price of GBX 1,674 ($21.87) per share, for a total transaction of £117.18 ($153.12).
Emma Walmsley also recently made the following trade(s):
- On Tuesday, July 9th, Emma Walmsley bought 8 shares of GlaxoSmithKline stock. The shares were acquired at an average price of GBX 1,636 ($21.38) per share, for a total transaction of £130.88 ($171.02).
- On Tuesday, June 11th, Emma Walmsley bought 7 shares of GlaxoSmithKline stock. The shares were acquired at an average price of GBX 1,585 ($20.71) per share, for a total transaction of £110.95 ($144.98).
GlaxoSmithKline stock opened at GBX 1,659.60 ($21.69) on Thursday. The stock has a 50-day moving average price of GBX 1,651.25. The stock has a market cap of $82.78 billion and a P/E ratio of 18.69. The company has a current ratio of 0.71, a quick ratio of 0.44 and a debt-to-equity ratio of 1,127.74. GlaxoSmithKline plc has a 12 month low of GBX 1,408.80 ($18.41) and a 12 month high of GBX 1,749.40 ($22.86).
Several equities analysts recently weighed in on the company. Deutsche Bank reiterated a “hold” rating and set a GBX 1,620 ($21.17) target price (up from GBX 1,575 ($20.58)) on shares of GlaxoSmithKline in a research report on Friday, July 26th. Credit Suisse Group set a GBX 1,700 ($22.21) target price on GlaxoSmithKline and gave the stock a “neutral” rating in a research report on Thursday, July 25th. HSBC set a GBX 1,942 ($25.38) target price on GlaxoSmithKline and gave the stock a “buy” rating in a research report on Tuesday, July 16th. UBS Group reiterated a “neutral” rating and set a GBX 1,610 ($21.04) target price (up from GBX 1,610 ($21.04)) on shares of GlaxoSmithKline in a research report on Thursday, July 25th. Finally, Barclays reiterated an “equal weight” rating on shares of GlaxoSmithKline in a research report on Thursday, July 25th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of GBX 1,638.06 ($21.40).
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Featured Article: Why is the Consumer Price Index (CPI) important?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.